SION · XBRL financial data

Sionna Therapeutics financial statements, every quarter

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SION's year ends in late December)

In thousands of dollars	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	13,668	15,383	16,044	15,168*	18,963	21,864
General and administrative	5,991	6,523	7,761	8,444*	10,636	10,606
Total operating expenses	19,659	21,906	23,805	23,612*	29,599	32,470
Other operating income (expense)	—	171	—	—	—	(3)
Operating income (loss)	(19,659)	(21,906)	(23,805)	(23,612)*	(29,599)	(32,470)
Interest income	3,000	3,667	3,456	3,172*	2,820	2,587
Income tax expense (benefit)	—	—	—	year only	—	—
Net income (loss)	(16,482)	(18,068)	(20,278)	(20,440)*	(26,779)	(29,886)
Earnings per share, basic USD per share	(620.00)	(410.00)	(0.46)	—	(0.60)	(0.66)
Earnings per share, diluted USD per share	(620.00)	(410.00)	(0.46)	—	(0.60)	(0.66)
Weighted average shares, basic thousands of shares	26,596	44,117	44,255	44,635*	44,922	45,149
Weighted average shares, diluted thousands of shares	26,596	44,117	44,255	44,635*	44,922	45,149

Fiscal quarters (SION's year ends in late December)

In thousands of dollars	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	82,695	40,985	50,831	58,451	63,324	63,322
Prepaid and other current assets	4,014	4,175	3,999	5,537	4,809	5,099
Total current assets	273,680	266,746	252,328	241,419	220,959	216,130
Property and equipment, net	2,393	2,246	2,144	2,225	2,071	1,916
Right-of-use asset	7,617	7,395	7,165	6,926	6,680	6,424
Total assets	369,674	352,048	339,270	325,953	305,039	283,249
Accrued liabilities	3,389	5,468	6,929	9,668	6,328	8,875
Total current liabilities	9,527	7,550	9,851	11,712	9,776	10,782
Lease liability, non-current	8,378	8,069	7,751	7,408	7,055	6,692
Total liabilities	17,905	15,619	17,602	19,120	16,831	17,474
Accumulated deficit	(197,568)	(215,636)	(235,914)	(256,354)	(283,133)	(313,019)
Total stockholders' equity	351,769	336,429	321,668	306,833	288,208	265,775
Total liabilities and equity	369,674	352,048	339,270	325,953	305,039	283,249
Common shares outstanding (cover page) thousands of shares	44,124	44,140	44,629	44,998	45,150	45,212

Fiscal quarters (SION's year ends in late December)

In thousands of dollars	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(16,482)	(18,068)	(20,278)	(20,440)*	(26,779)	(29,886)
Stock-based compensation	2,094	2,840*	3,306*	3,826*	6,553	6,842*
Net cash from operating activities	(16,288)	(18,153)*	(15,230)*	(16,626)*	(21,840)	(22,220)*
Purchases of property and equipment	86	0*	87*	204*	0	0*
Net cash from investing activities	(141,194)	(23,245)*	23,102*	22,588*	24,820	21,469*
Net cash from financing activities	202,389	(312)*	1,974*	1,659*	1,893	749*
Net change in cash	44,907	(41,710)*	9,846*	7,621*	4,873	(2)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sionna Therapeutics	63,322	not reported	(22,220)*	45.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	175,700	110,000	100,100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	595	807	(7,169)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Amarin	156,512	39,550	9,223*	not reported	—	Q3 FY26 10-QSep 30, 2026
Rigel Pharmaceuticals	60,816	78,703	30,653*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Usana Health Sciences	168,560	223,273	23,319*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Altimmune	63,008	not reported	(24,221)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288,193	1,010	(25,049)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	67,836	not reported	(32,501)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.